BAVA Bavarian Nordic A/S

Bavarian Nordic Announces the Resignation of Tommi Kainu as EVP and Chief Business Officer

Bavarian Nordic Announces the Resignation of Tommi Kainu as EVP and Chief Business Officer

COPENHAGEN, Denmark, March 26, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Tommi Kainu, MD, PhD has resigned his position as Executive Vice President and Chief Business Officer in the Company. He will continue to support Bavarian Nordic until the end of November 2021.

“On behalf of the entire Company, I want to thank Tommi for his significant contributions over the past four years. Tommi Joined Bavarian Nordic to build industry partnerships and pave the way for a commercial transformation of the company. With the successful acquisition of Encepur and Rabipur and the establishment of the commercial organization, these main objectives have been completed. As a consequence, Tommi has decided to pursue opportunities outside Bavarian Nordic and we wish him all the very best in his future endeavors,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic.

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit .

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 11 / 2021

Attachment



EN
26/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Bavarian Nordic lancerer næste del af aktietilbagekøbsprogram

Bavarian Nordic lancerer næste del af aktietilbagekøbsprogram KØBENHAVN, Danmark, 12. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) iværksætter nu den anden del af det planlagte aktietilbagekøbsprogram, hvorunder selskabet vil tilbagekøbe egne aktier for op til DKK 500 mio. i løbet af 2026. Den første del, som blev afsluttet tidligt i februar 2026, omfattede tilbagekøb af aktier for DKK 150 mio. Den anden del vil omfatte tilbagekøb af aktier for op til DKK 200 mio., som selskabet også vil beholde som egne aktier med det formål at tilpasse kapitalstrukturen. Aktietilbagekøbsprogrammet iværk...

 PRESS RELEASE

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program

Bavarian Nordic Launches Next Tranche of Share Buy-Back Program COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 million during 2026. The first tranche, completed in early February 2026, comprised buy-back of shares for DKK 150 million. The second tranche will comprise buy-back of shares for DKK 200 million, also to be held as treasury stock for the purpose of adjusting the capital structure. The share buy-back program is initia...

 PRESS RELEASE

Bavarian Nordic offentliggør årsrapport for 2025

Bavarian Nordic offentliggør årsrapport for 2025 KØBENHAVN, Danmark, 12. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag årsrapporten for 2025. De konsoliderede og reviderede finansielle resultater var i overensstemmelse med de foreløbige resultater, der blev offentliggjort den 12. februar 2026. Årsrapporten er vedhæftet og er desuden tilgængelig via . “Vores årsrapport for 2025 bekræfter de stærke foreløbige resultater, vi rapporterede i sidste måned, og vi er godt i gang med at gennemføre vores planer for 2026 med henblik på at levere fortsat vækst i vores Travel Healt...

 PRESS RELEASE

Bavarian Nordic Publishes Annual Report 2025

Bavarian Nordic Publishes Annual Report 2025 COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced on February 12, 2026. The report is attached and available on . “Our 2025 annual report confirms the strong preliminary results reported last month and we are well underway in the execution of our plans for 2026 to deliver continued growth in our Travel Health business. Organic growth in our core products, rabies and TBE, remains strong, and is furt...

 PRESS RELEASE

Paul Chaplin fratræder som administrerende direktør i Bavarian Nordic

Paul Chaplin fratræder som administrerende direktør i Bavarian Nordic KØBENHAVN, Danmark, 2. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at bestyrelsen har indgået en aftale med administrerende direktør, Paul Chaplin, som ønsker at træde tilbage af personlige årsager. Paul Chaplin vil fortsætte i sin rolle indtil udgangen af 2026 eller indtil en efterfølger er identificeret. Bestyrelsen har igangsat processen med at identificere en ny administrerende direktør. Paul Chaplin har været hos Bavarian Nordic siden 1999 og blev udnævnt til administrerende direktør i 2014....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch